Search

Your search keyword '"Siebenhaar, Frank"' showing total 502 results

Search Constraints

Start Over You searched for: Author "Siebenhaar, Frank" Remove constraint Author: "Siebenhaar, Frank"
502 results on '"Siebenhaar, Frank"'

Search Results

4. Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus

5. Non–Skin Related Symptoms Are Common in Chronic Spontaneous Urticaria and Linked to Active and Uncontrolled Disease: Results From the Chronic Urticaria Registry

8. Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM

12. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT

15. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives

16. Mastocytoses

17. Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond

18. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium

19. Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis

20. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium

22. Disease modification in chronic spontaneous urticaria.

25. Non-Skin-Related Symptoms are Common in Chronic Spontaneous Urticaria and Linked to Active and Uncontrolled Disease: Results from CURE

27. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review

29. COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)

30. Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions

34. Prevalence Of The KIT D816V Mutation In Peripheral Blood (PB) Of Patients With Evidence Of Systemic Mast Cell Activation (MCA): Results Of The Prospective, Multi-centered, Global PROSPECTOR Clinical Trial

35. Avapritinib Decreased Symptom Burden in Patients With Indolent Systemic Mastocytosis in the Registrational Double-Blind, Placebo-Controlled PIONEER Study

36. Exploring the Spectrum of Indolent Systemic Mastocytosis: Analysis of High-Risk Disease Features in the PIONEER Study

37. Initial Results from Summit: An On-going, 3-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of Bezuclastinib in Adult Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

40. Obituary: Professor Marcus Maurer, Berlin, Germany.

43. Mastozytose

45. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome

47. MPN-524 Reductions in Indolent Systemic Mastocytosis Biomarker Burden With Avapritinib in the Registrational, Double-Blind, Placebo-Controlled PIONEER Trial

48. POSTER: MPN-524 Reductions in Indolent Systemic Mastocytosis Biomarker Burden With Avapritinib in the Registrational, Double-Blind, Placebo-Controlled PIONEER Trial

Catalog

Books, media, physical & digital resources